Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Ewelina Siwiak-Niedbalska"'
Autor:
Maja Sołtyka-Krajewska, Marcin Ziemniak, Anna Zawadzka-Kazimierczuk, Paulina Skrzypczyk, Ewelina Siwiak-Niedbalska, Anna Jaśkiewicz, Rafał Zieliński, Izabela Fokt, Stanisław Skóra, Wiktor Koźmiński, Krzysztof Woźniak, Waldemar Priebe, Beata Pająk-Tarnacka
Publikováno v:
Biomedicines, Vol 12, Iss 10, p 2240 (2024)
Background: One defining feature of various aggressive cancers, including glioblastoma multiforme (GBM), is glycolysis upregulation, making its inhibition a promising therapeutic approach. One promising compound is 2-deoxy-d-glucose (2-DG), a d-gluco
Externí odkaz:
https://doaj.org/article/6d606b7bd79e4c7ba8de139e5102bb5f
Publikováno v:
Biomedicines, Vol 10, Iss 11, p 2799 (2022)
Glioblastoma multiforme (GBM) is the most common primary malignant brain tumor in adults with a poor prognosis. Despite significant progress in drug development, the blood–brain barrier (BBB) continues to limit the use of novel chemotherapeutics. T
Externí odkaz:
https://doaj.org/article/52984fec04664b2380270c0d309d5d14
Autor:
Beata Pająk, Ewelina Siwiak-Niedbalska, Anna Jaśkiewicz, Maja Sołtyka, Rafał Zieliński, Tomasz Domoradzki, Izabela Fokt, Stanisław Skóra, Waldemar Priebe
Publikováno v:
Biomedicines, Vol 9, Iss 12, p 1749 (2021)
Over the last decade, we have seen tremendous progress in research on 2-deoxy-D-glucose (2-DG) and its analogs. Clinical trials of 2-DG have demonstrated the challenges of using 2-DG as a monotherapy, due to its poor drug-like characteristics, leadin
Externí odkaz:
https://doaj.org/article/0059a481e2a447b882323f913e1c01d8
Autor:
Ewelina Siwiak-Niedbalska, Waldemar Priebe, Izabela Fokt, Rafal Zielinski, Stanislaw Skora, Tomasz Domoradzki, Anna Jaśkiewicz, Beata Pająk, Maja Sołtyka
Publikováno v:
Biomedicines
Biomedicines, Vol 9, Iss 1749, p 1749 (2021)
Biomedicines; Volume 9; Issue 12; Pages: 1749
Biomedicines, Vol 9, Iss 1749, p 1749 (2021)
Biomedicines; Volume 9; Issue 12; Pages: 1749
Over the last decade, we have seen tremendous progress in research on 2-deoxy-D-glucose (2-DG) and its analogs. Clinical trials of 2-DG have demonstrated the challenges of using 2-DG as a monotherapy, due to its poor drug-like characteristics, leadin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5e85e1b974cc06f672f57aa9de6bfe6
http://europepmc.org/articles/PMC8698815
http://europepmc.org/articles/PMC8698815